| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IGF2BP2 |
| Uniprot No | Q9Y6M1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-220aa |
| 氨基酸序列 | MASMTGGQQMGRGSEFMMNKLYIGNLSPAVTADDLRQLFGDRKLPLAGQV LLKSGYAFVDYPDQNWAIRAIETLSGKVELHGKIMEVDYSVSKKLRSRKI QIRNIPPHLQWEVLDGLLAQYGTVENVEQVNTDTETAVVNVTYATREEAK IAMEKLSGHQFENYSFKISYIPDEEVSSPSPPQRAQRGDHSSREQGHAPG GTSQARQIDFPLRILVPTQFVGAIIGKEGLTIKNITLEHHHHHH |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IGF2BP2重组蛋白的3篇代表性文献示例(注：文献信息为示例，实际引用需根据真实文献调整)：
---
1. **文献名称**：*IGF2BP2 promotes tumor progression by destabilizing mRNA via interaction with target transcripts in colorectal cancer*
**作者**：Huang, X., Zhang, H., & Guo, T. (2018)
**摘要**：本研究利用重组IGF2BP2蛋白进行体外RNA结合实验，发现其通过结合特定mRNA(如MYC和MDR1)的3'UTR增强稳定性，促进结直肠癌细胞增殖和化疗耐药。重组蛋白的KH结构域突变体证实了其RNA结合功能的关键性。
---
2. **文献名称**：*Structural insights into the RNA-binding properties of IGF2BP2 and its role in metabolic disorders*
**作者**：Li, Y., Wang, Q., & Chen, Z. (2020)
**摘要**：通过重组表达人源IGF2BP2蛋白，结合X射线晶体学分析，揭示了其RNA结合域的精细结构。功能实验表明，重组蛋白通过调控胰岛素信号通路相关基因(如IGF2和IRS1)的翻译影响2型糖尿病发展。
---
3. **文献名称**：*Recombinant IGF2BP2 as a novel biomarker for pancreatic cancer diagnosis*
**作者**：Kim, S., Patel, R., & Nguyen, H. (2021)
**摘要**：研究开发了高纯度重组IGF2BP2蛋白，用于血清抗体检测。临床样本分析显示，IGF2BP2自身抗体在胰腺癌患者中显著升高，提示其作为非侵入性诊断标志物的潜力。
---
**提示**：实际文献检索建议使用以下关键词：
- **数据库**：PubMed、Web of Science
- **关键词**：*IGF2BP2 recombinant protein, IGF2BP2 expression and purification, IGF2BP2 RNA-binding function*
- **筛选策略**：优先选择近5年发表、高被引或发表在权威期刊(如*Nature Communications*, *Nucleic Acids Research*)的研究。
The insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) is a member of the conserved RNA-binding protein family that regulates gene expression at the post-transcriptional level. It binds to target mRNAs, influencing their stability, localization, and translation. IGF2BP2 is particularly known for its role in embryonic development, cell proliferation, and metabolism by interacting with transcripts encoding insulin-like growth factors (IGFs) and other growth-regulatory proteins. Dysregulation of IGF2BP2 has been linked to metabolic disorders, including type 2 diabetes, and cancers, where it often acts as an oncogene by promoting tumor growth, metastasis, and chemoresistance.
Recombinant IGF2BP2 protein is engineered in vitro using expression systems like *E. coli* or mammalian cells, enabling precise study of its molecular functions. This purified protein retains RNA-binding activity and is used to investigate interactions with mRNA targets, such as *IGF2*, *MYC*, and *HMGA1*, which are critical in cellular proliferation and differentiation. Researchers employ it to dissect IGF2BP2's role in RNA metabolism, including its contribution to stress granule formation or mRNA stabilization under stress conditions. Additionally, recombinant IGF2BP2 aids in drug discovery, serving as a target for inhibitors aimed at disrupting its oncogenic activity in cancers. Its structural domains, including KH domains for RNA binding, are analyzed to design therapeutic interventions. Current studies focus on elucidating IGF2BP2's regulatory networks and its potential as a biomarker or therapeutic target in metabolic and neoplastic diseases.
×
